{"id":2878,"date":"2026-03-10T13:43:53","date_gmt":"2026-03-10T06:43:53","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2878"},"modified":"2026-05-06T10:08:05","modified_gmt":"2026-05-06T03:08:05","slug":"varicella-and-the-barycela-vaccine-for-disease-prevention","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/varicella-and-the-barycela-vaccine-for-disease-prevention","title":{"rendered":"VARICELLA AND THE BARYCELA VACCINE FOR DISEASE PREVENTION"},"content":{"rendered":"

I. VARICELLA<\/b><\/span><\/p>\n

1. Causative virus<\/b>
\n<\/span>Causative agent: Varicella-Zoster virus (VZV) \u2013 MAV\/06 strain, belonging to the Herpesviridae family, Alphaherpesvirinae subfamily.<\/span>
\n<\/span>Characteristics:<\/b> An enveloped virus with a double-stranded DNA (dsDNA) genome.<\/span>
\n<\/span>Mode of transmission:<\/b> Spread via respiratory droplets or direct contact with vesicular fluid. Notably, the virus can be transmitted even before the onset of rash<\/span><\/span><\/p>\n

\"\"<\/a>Varicella-Zoster virus<\/span><\/p>\n

2. Symptoms and complications<\/strong><\/span><\/p>\n

Incubation period:<\/b> Lasts from 10 to 21 days.<\/span><\/span><\/p>\n

Symptoms:<\/b> Fever, fatigue, and loss of appetite, followed by a rash with vesicular lesions appearing in successive crops. The rash typically begins on the face, chest, and back before spreading across the body. At any given time, multiple lesion stages may be present simultaneously, including macules, papules, vesicles, and crusts.<\/span><\/span><\/p>\n

Serious complications:<\/b> Without appropriate care, varicella may lead to complications such as pneumonia, encephalitis, or skin infections. In the long term, the virus can remain latent in the sensory ganglia and later reactivate as herpes zoster (shingles), particularly in older age or immunocompromised individuals.<\/span><\/span><\/p>\n

3. Diagnosis based on clinical and paraclinical findings<\/b><\/span><\/p>\n

Clinical diagnosis:<\/b> Erythematous rash with vesicular lesions appearing in multiple crops and at different stages simultaneously (macules, papules, vesicles, crusts). The rash spreads from the face, chest, and back to the entire body, often accompanied by intense pruritus.<\/span><\/span><\/p>\n

Paraclinical diagnosis:<\/b> Serology: anti-VZV IgM (marker of acute infection); PCR: detection of VZV DNA in vesicular fluid or blood; Direct fluorescent antibody (DFA) testing from skin lesion samples.<\/span><\/span><\/p>\n

4. Treatment<\/b>
\n<\/span>Symptomatic treatment, anti-pruritic management, and proper skin hygiene; severe cases may be treated with acyclovir.<\/span><\/span><\/p>\n

5. BARYCELA VACCINE<\/b><\/span><\/p>\n

BARYCELA inj. is a live attenuated varicella vaccine derived from the Varicella-Zoster virus (attenuated MAV\/06 strain), designed to induce an immune response against varicella. The BARYCELA inj. varicella vaccine is manufactured in compliance with Good Manufacturing Practice (GMP), ensuring international quality standards.<\/span><\/p>\n

Detailed vaccine information:<\/b><\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Vaccine<\/span><\/td>\nBARYCELA<\/span><\/span><\/p>\n

 <\/td>\n<\/tr>\n

Manufacturer<\/span><\/td>\nGC Biopharma Corp., Republic of Korea<\/span><\/td>\n<\/tr>\n
Composition<\/span><\/td>\nLyophilised vaccine:<\/span>
\n<\/span> \u2714 Live attenuated varicella virus<\/span>
\n<\/span> (Strain: MAV\/06, cell line: MRC-5) \u2265 3,800 PFU<\/span>
\n<\/span> \u2714 Potassium dihydrogen phosphate 0.06 mg<\/span>
\n<\/span> \u2714 Dibasic sodium phosphate hydrate 1.14 mg<\/span>
\n<\/span> \u2714 Sodium L-glutamate hydrate 0.40 mg<\/span>
\n<\/span> \u2714 Sucrose 18.21 mg<\/span>
\n<\/span> \u2714 L-cysteine 0.18 mg<\/span>
\n<\/span> \u2714 Glycine 1.82 mg<\/span>
\n<\/span> \u2714 Disodium edetate hydrate 0.18 mg<\/span>
\n<\/span> \u2714 Urea 0.87 mg<\/span>
\n<\/span> \u2714 Gelatin 8.74 mg<\/span>
\n<\/span> Diluent: Water for injection: 0.7 mL<\/span><\/span><\/span> <\/td>\n<\/tr>\n
Vaccine type<\/span><\/td>\nLive attenuated<\/span><\/td>\n<\/tr>\n
Storage<\/span><\/td>\n2\u20138\u00b0C<\/span><\/td>\n<\/tr>\n
Shelf life<\/span><\/td>\n24 months<\/span><\/td>\n<\/tr>\n
Vaccination schedule<\/span><\/td>\nDose 1: typically administered from 12 months of age.<\/span>
\n<\/span> Dose 2: administered approximately 3 months after Dose 1 to enhance immunogenicity.<\/span><\/span><\/td>\n<\/tr>\n
Route of administration<\/span><\/td>\nSubcutaneous<\/span><\/td>\n<\/tr>\n
Injection site<\/span><\/td>\nYoung children: anterolateral thigh<\/span><\/p>\n

Older children: deltoid region (upper arm)<\/span><\/td>\n<\/tr>\n

Dose<\/span><\/td>\n0.5 mL\/dose<\/span><\/td>\n<\/tr>\n
Indication<\/span><\/td>\nChildren aged 12 months to 12 years<\/span><\/td>\n<\/tr>\n
Contraindications<\/span><\/td>\n \u2714 Severe allergy (anaphylaxis) to any component of the vaccine (e.g. gelatin).<\/span>
\n<\/span> \u2714 Immunocompromised individuals (congenital disorders, advanced HIV infection, undergoing chemotherapy\/radiotherapy, or receiving high-dose immunosuppressive therapy).<\/span>
\n<\/span> \u2714 Pregnant women or those planning pregnancy within 3 months after vaccination.<\/span>
\n<\/span> \u2714 Individuals with acute high fever or severe systemic illness (vaccination should be deferred, not an absolute contraindication).<\/span>
\n<\/span> \u2714 History of severe reaction to a previous dose.<\/span>
\n<\/span> \u2714 Untreated active tuberculosis.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Quality control:<\/b><\/span><\/p>\n\n\n\n\n\n\n
\u2714 Seed lot<\/span><\/td>\n\u2714 Bulk intermediate stage<\/span><\/td>\n<\/tr>\n
\u2714 Cell substrate<\/span><\/td>\n\u2714 Final bulk<\/span><\/td>\n<\/tr>\n
\u2714 Virus harvest stage<\/span><\/td>\n\u2714 Final product<\/span><\/td>\n<\/tr>\n
\u2714 Purification<\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Final product testing:<\/b><\/span><\/p>\n\n\n\n\n\n\n\n
\u2714 Appearance<\/span><\/td>\n\u2714 Residual moisture<\/span><\/td>\n<\/tr>\n
\u2714 Reconstitution time<\/span><\/td>\n\u2714 Residual BSA content<\/span><\/td>\n<\/tr>\n
\u2714 pH<\/span><\/td>\n\u2714 Urea content<\/span><\/td>\n<\/tr>\n
\u2714 Potency: Varicella<\/span><\/td>\n\u2714 Sterility<\/span><\/td>\n<\/tr>\n
\u2714 Identification: Varicella<\/span><\/td>\n\u2714 Mycoplasma<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/a><\/p>\n

BARYCELA vaccine<\/span><\/i><\/span><\/p>\n

 <\/p>\n

Source: WHO, CDC, KFDA (Republic of Korea), MSD, Infectious Diseases Textbook \u2013 Medical Publishing House.<\/span><\/p>\n

Dr. Phan Thi Kim Linh, Quality System Management Department<\/i><\/b><\/p>\n

According to: <\/span>NATIONAL INSTITUTE FOR CONTROL OF VACCINES AND BIOLOGICALS<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

I. VARICELLA 1. Causative virus Causative agent: Varicella-Zoster virus (VZV) \u2013 MAV\/06 strain, belonging to the Herpesviridae family, Alphaherpesvirinae subfamily. Characteristics: An enveloped virus with a double-stranded DNA (dsDNA) genome. Mode of transmission: Spread via respiratory droplets or direct contact with vesicular fluid. Notably, the virus can be transmitted even before the onset of rash […] <\/p>\n","protected":false},"author":4,"featured_media":2793,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-2878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/comments?post=2878"}],"version-history":[{"count":3,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2878\/revisions"}],"predecessor-version":[{"id":2881,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2878\/revisions\/2881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media\/2793"}],"wp:attachment":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media?parent=2878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/categories?post=2878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/tags?post=2878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}